Copyright
©The Author(s) 2023.
World J Diabetes. Apr 15, 2023; 14(4): 396-411
Published online Apr 15, 2023. doi: 10.4239/wjd.v14.i4.396
Published online Apr 15, 2023. doi: 10.4239/wjd.v14.i4.396
Figure 1 Pathophysiology of diabesity as evidenced by recent literature.
IL-2: Interleukin-2; TNF-α: Tumor necrosis alpha; IR: Insulin resistance.
Figure 2 The mechanisms of actions of glucagon-like insulinotropic peptide-1 agonists in improving diabesity.
Figure 3 Mechanisms of actions of sodium glucose cotransporter-2 inhibitors in improving diabesity and their potential effects on organ protection such as kidney and heart.
EF: Ejection fraction; SGLT-2i: Sodium glucose cotransporter-2 inhibitor.
Figure 4 An evidence-based management algorithm for the management of diabesity.
GLP-1RA: Glucagon-like insulinotropic peptide; MNT: Medical nutrition therapy; SGLT-2i: Sodium glucose cotransporter-2 inhibitor.
- Citation: Michaelidou M, Pappachan JM, Jeeyavudeen MS. Management of diabesity: Current concepts. World J Diabetes 2023; 14(4): 396-411
- URL: https://www.wjgnet.com/1948-9358/full/v14/i4/396.htm
- DOI: https://dx.doi.org/10.4239/wjd.v14.i4.396